Silverberg Bernstein Capital Management LLC Has $737,000 Holdings in Accuray Incorporated (NASDAQ:ARAY)

Silverberg Bernstein Capital Management LLC trimmed its stake in Accuray Incorporated (NASDAQ:ARAY) by 10.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 372,452 shares of the medical equipment provider’s stock after selling 43,332 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.37% of Accuray worth $737,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Accuray by 0.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after purchasing an additional 7,500 shares in the last quarter. Foundry Partners LLC boosted its position in Accuray by 51.3% in the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after buying an additional 741,900 shares in the last quarter. Geode Capital Management LLC grew its stake in Accuray by 2.1% during the third quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock worth $3,924,000 after buying an additional 45,548 shares during the last quarter. State Street Corp increased its holdings in shares of Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock worth $3,410,000 after buying an additional 70,008 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Accuray by 27.2% in the third quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after acquiring an additional 124,459 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Up 0.5 %

NASDAQ:ARAY opened at $2.21 on Wednesday. The stock has a market cap of $222.25 million, a price-to-earnings ratio of -13.00 and a beta of 1.47. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The stock has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $1.92. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $2.99.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The company had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. During the same quarter in the prior year, the company earned ($0.03) earnings per share. As a group, equities analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.